Vimarsana
Biggest News Aggregation in the World

Page 2 - Cardiac Resynchronization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cardiac Resynchronization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cardiac Resynchronization Today - Breaking & Trending Today

Global Implantable Defibrillators Market Report to 2030 - - Vimarsana News

Global Implantable Defibrillators Market Report to 2030 -

Dublin, May 05, 2022 (GLOBE NEWSWIRE) -- The "Implantable Defibrillators Market by Product Type [Transvenous Implantable Cardioverter-Defibrillator,...

Medtronic appoints new Operating Unit Presidents - Vimarsana News

Medtronic appoints new Operating Unit Presidents

Que Dallara joins as EVP & President, Diabetes Mike Marinaro named President, Surgical Robotics Dr. Kweli Thompson named President, Cardiac Rhythm Management DUBLIN, March 17, 2022 /PRNewswire/... | March 17, 2022

Medtronic appoints new Operating Unit Presidents - Vimarsana News

Medtronic appoints new Operating Unit Presidents

/PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced leadership transitions for three of its Operating Units –...

Global Cardiac Resynchronization Therapy Markets Analysis & - Vimarsana News

Global Cardiac Resynchronization Therapy Markets Analysis &

Dublin, March 04, 2022 (GLOBE NEWSWIRE) -- The "Cardiac Resynchronization Therapy Market Size, Share & Trends Analysis Report by Product...

Marburg Virus Disease Pipeline Offers Promising New Options for Treatment - Vimarsana News

Marburg Virus Disease Pipeline Offers Promising New Options for Treatment

Bavarian Nordic, BioCryst Pharmaceuticals, Integrated Biotherapeutics, Geovax, Batavia Biosciences, Globavir Biosciences, Collaboration Pharmaceuticals, Emergex Vaccines, ReiThera, Emergent BioSolutions, Mapp Biopharmaceuticals, Biofactura, Alkido Pharma, Flow Pharma, and others are developing potential drug candidates to improve the Marburg Virus Disease treatment scenario.  BioCryst is developing galidesivir in partnership with U.S. government agencies and other institutions. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BioCryst to ...